Zifam CS1/CS2

Zifam CS1/CS2

cefoperazone + sulbactam

Manufacturer:

Zifam Pinnacle

Distributor:

Pyrex
Concise Prescribing Info
Contents
Per Zifam CS1 vial Sulbactam Na 500 mg, cefoperazone Na 500 mg. Per Zifam CS2 vial Sulbactam Na 1000 mg, cefoperazone Na 1000 mg
Indications/Uses
Treatment of infections eg resp tract infections (upper & lower); UTI (upper & lower); peritonitis, cholecystitis, cholangitis & other intra-abdominal infections; septicemia; meningitis; skin & soft tissue infections; bone & joint infections; pelvic inflammatory disease, endometriosis, gonorrhea & other genital tract infections. Alone or in in combination w/ other antibiotics.
Dosage/Direction for Use
Adult 2-4 g/day IV or IM 12 hrly. Severe or refractory infections Max: 8 g/day. Patients w/ CrCl 15-30 mL/min Max daily dose: 2 g sulbactam, CrCl <15 mL/min Max daily dose: 1 g sulbactam. Childn 40-80 mg/kg/day (ie 20-40 mg/kg/day cefoperazone activity) in 2-4 equally divided doses. Serious or refractory infections Max: 160 mg/kg/day (ie 80 mg/kg/day cefoperazone activity) in 2-4 equally divided doses. Neonates (1st wk of life) 12 hrly.
Contraindications
Hypersensitivity to penicillins or cephalosporins.
Special Precautions
Hepatic disease, biliary obstruction, renal dysfunction. Risk of vit K deficiency. Prolonged use may cause an overgrowth of nonsusceptible organisms. Check periodically the renal, hepatic & hematopoietic systems particularly in neonates. Alcohol consumption. Pregnancy & lactation.
Adverse Reactions
Diarrhea, nausea, vomiting, maculopapular rash, urticaria, decreased Hb & hematocrit, transient eosinophilia, thrombocytopenia, hypoprothrombinemia, transient elevations of liver function tests.
MIMS Class
ATC Classification
J01DD62 - cefoperazone and beta-lactamase inhibitor ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Presentation/Packing
Form
Zifam CS2 injectable powd
Packing/Price
2 g x 1's
Form
Zifam CS1 injectable powd
Packing/Price
1 g x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in